1. Baumann S, Eddine AN, Kaufmann SHE. Progress in tuberculosis vaccine development. Curr Opin Immunol. 2006 Aug; 18(4): 438-48. DOI: 10.1016/j.coi.2006.05.016 [ DOI] [ PubMed] 2. Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E. Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf. 2011 Feb; 6(1): 17-22. DOI: 10.2174/157488611794479946 [ DOI] [ PubMed] 3. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicitiy of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct; 174(8): 935-52. DOI: 10.1164/rccm.200510-1666ST [ DOI] [ PubMed] 4. Yildiz A, Sever MS, Türkmen A, Ecder T, Beşişik F, Tabak L, et al. Tuberculosis after renal transplantation: experience of one Turkish center. Nephrol Dial Transplant. 1998 Jul; 13(7): 1872-75. DOI: 10.1093/ndt/13.7.1872 [ DOI] [ PubMed] 5. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis druginduced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007 Nov; 87(6): 551-56. DOI: 10.1016/j.tube.2007.05.012 [ DOI] [ PubMed] 6. Sarich TC, Adams SP, Petricca G, Wright JM. Inhibition of isoniazidinduced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. J Pharmacol Exp Ther. 1999 May; 289(2): 695-702. [ PubMed] 7. Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghi M, Gholami Kh , Mahjub R. Antituberculosis Drug- Induced Hepatotoxicity in Iranian Tuberculosis Patients: Role of Isoniazid Metabolic Polymorphism. Iran J Pharm Res. 2011; 10(3): 633-39. [ PubMed] 8. Law J, Jacobsen SE. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet. 2010 Mar; 11(3): 204-20. DOI: 10.1038/nrg2719 [ DOI] [ PubMed] 9. Boakye-Appiah JK, Steinmetz AR, Pupulampu P, Ofori-Yirenkyi S, Tetteh I, Frimpong M, et al. High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana. Int J Mycobacteriol. 2016 Jun; 5(2): 226-30. DOI: 10.1016/j.ijmyco.2016.02.004 [ DOI] [ PubMed] 10. Cabibbe AM, Cirillo DM. Best approaches to drug-resistance surveillance at the country level. Int J Mycobacteriol. 2016 Dec; 5(1): S40-S41. DOI: 10.1016/j.ijmyco.2016.09.010 [ Article] [ DOI] 11. Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess. 2015 May; 19(34): 1-188. DOI: 10.3310/hta19340 [ DOI] [ PubMed] 12. Dziadek B, Brzostek A, Grzybowski M, Fol M, Krupa A, Kryczka J, et al. Mycobacterium tuberculosis AtsG (Rv0296c), GlmU (Rv1018c) and SahH (Rv3248c) Proteins Function as the Human IL-8-Binding Effectors and Contribute to Pathogen Entry into Human Neutrophils. PLoS One. 2016; 11(2): e0148030. DOI: 10.1371/journal.pone.0148030 [ DOI] [ PubMed] 13. Havumaki J, Hillemann D, Ismail N, Omar SV, Georghiou SB, Schumacher SG, et al. Comparative accuracy of the REBA MTB MDR and Hain MTBDRplus line probe assays for the detection of multidrug-resistant tuberculosis: A multicenter, non-inferiority study. PLoS One. 2017; 12(3): e0173804. DOI: 10.1371/journal.pone.0173804 [ DOI] [ PubMed] 14. Korycka-Machala M, Brzostek A, Dziadek B, Kawka M, Poplawski T, Witczak ZJ, et al. Evaluation of the Mycobactericidal Effect of Thio-functionalized Carbohydrate Derivatives. Molecules. 2017 May; 22(5): 812. DOI: 10.3390/molecules22050812 [ DOI] [ PubMed] 15. Laborde J, Deraeve C, de Mesquita Vieira FG, Sournia-Saquet A, Rechignat L, Villela AD, et al. Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy. J Inorg Biochem. 2018 Feb; 179: 71-81. DOI: 10.1016/j.jinorgbio.2017.11.013 [ DOI] [ PubMed] 16. Roshdi Maleki M, Moaddab S. [Drug susceptibility pattern of Mycobacterium tuberculosisstrains to first and second line drugs in Tabriz, Iran]. Iran J Med Microbiol. 2009; 3(1): 18-24. [Article in Persian] [ Article] 17. Chowdhury A, Paul P, Choudhury MD. High throughput screening of 7-methylpicene-1,2-diol as arylamine N-acetyltransferase (NAT) inhibitor to establish a isoniazid supplement in anti-tubercular therapy. Comb Chem High Throughput Screen. 2013 Nov; 16(9): 721-25. DOI: 10.2174/13862073113169990004 [ DOI] [ PubMed] 18. Kim KH, An DR, Yoon HJ, Yang JK, Suh SW. Structure of Mycobacterium smegmatis Eis in complex with paromomycin. Acta Crystallogr F Struct Biol Commun. 2014 Sep; 70(Pt 9): 1173-79. DOI: 10.1107/S2053230X14017385 [ DOI] [ PubMed] 19. Joshi RS, Jamdhade MD, Sonawane MS, Giri AP. Resistome analysis of Mycobacterium tuberculosis: Identification of aminoglycoside 2'-Nacetyltransferase (AAC) as co-target for drug desigining. Bioinformation. 2013; 9(4): 174-81. DOI: 10.6026/97320630009174 [ DOI] [ PubMed] 20. Houghton JL, Green KD, Pricer RE, Mayhoub AS, Garneau-Tsodikova S. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. J Antimicrob Chemother. 2013 Apr; 68(4): 800-5. DOI: 10.1093/jac/dks497 [ DOI] [ PubMed] 21. Field SK, Escalante P, Fisher DA, Ireland B, Irwin RS, CHEST Expert Cough Panel. Cough Due to TB and Other Chronic Infections: CHEST Guideline and Expert Panel Report. Chest. 2018 Feb; 153(2): 467-97. DOI: 10.1016/j.chest.2017.11.018 [ DOI] [ PubMed] 22. Kiran D, Podell BK, Chambers M, Basaraba RJ. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. Semin Immunopathol. 2016 Mar; 38(2): 167-83. DOI: 10.1007/s00281-015-0537-x [ DOI] [ PubMed] 23. Willby MJ, Green KD, Gajadeera CS, Hou C, Tsodikov OV, Posey JE, et al. Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in Mycobacterium tuberculosis. ACS Chem Biol. 2016 Jun; 11(6): 1639-46. DOI: 10.1021/acschembio.6b00110 [ DOI] [ PubMed] 24. Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, van den Hof S, Dewan PK, et al. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India. PLoS One. 2015 May; 10(5): e0126065. DOI: 10.1371/journal.pone.0126065 [ DOI] [ PubMed] 25. Sandy J, Holton S, Fullam E, Sim E, Noble M. Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 2005 Mar; 14(3): 775-82. DOI: 10.1110/ps.041163505 [ DOI] [ PubMed] 26. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, et al. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol. 2001 Oct; 42(2): 309-17. DOI: 10.1046/j.1365-2958.2001.02648.x [ DOI] [ PubMed] 27. Westwood I, Bhakta S, Russell AJ, Fullam E, Anderton MC, Kawamura A, et al. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein Cell. 2010 Jan; 1(1): 82-95. DOI: 10.1007/s13238-010-0006-1 [ DOI] [ PubMed] 28. Zabost A, Brzezińska S, Kozińska M, Błachnio M, Jagodziński J, Zwolska Z, et al. Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients. Biomed Res Int. 2013; 2013: 853602. DOI: 10.1155/2013/853602 [ DOI] [ PubMed] 29. Doustdar F, Khosravi A, Farnia P, Bahremand A. [Characterization of rpoB mutations in rifampin-resistant isolates of Mycobacterium tuberculosis cultured from the Iranian patients]. Iran J Med Microbiol. 2007; 1(1): 17-22. [Article in Persian] [ View at Publisher] 30. Pourhajibagher M, Nasrollahi M, Musavi S, Rahimi-Esboei B, Ghorbani Pashakolaei A. [Drug Resistance in Mycobacterium Tuberculosis Isolates to Isoniazid and Rifampin]. J Babol Uni Med Sci. 2012; 14(3): 66-72. [Article in Persian] [ View at Publisher]
|